01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

Open Orphan PLC #ORPH – NEJM Opinion Piece July 22, 2021 – Posted in: Open Orphan (ORPH)

The New England Journal of Medicine (NEJM) publishes editorial relating to Human Challenge Programme Open Orphan (AIM: ORPH), a rapidly growing specialist clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, confirms that an editorial opinion piece regarding the UK Government’s Human Challenge Programme has been published in the latest edition of the New England Journal of Medicine (NEJM). The piece, titled ‘Establishing the Model during an Evolving Pandemic’, explores the extensive…

Continue reading

Open Orphan #ORPH – World’s first Covid-19 human challenge study to expand July 14, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan plc, is continuing to work with the UK Government to inoculate up to 20 further volunteers as part of the world’s first COVID-19 characterisation study. As part of the characterisation study, researchers aimed to identify a dose of COVID-19 that…

Continue reading

Open Orphan #ORPH – COVID-19 Human Challenge Programme update March 25, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces an update in the world’s first COVID-19 characterisation study. Following Research Ethics Committee approval on 17 February 2021, hVIVO, a subsidiary of Open Orphan, began the study at the Royal Free London NHS Foundation Trust earlier this month. The first three volunteers have now successfully completed…

Continue reading

Open Orphan #ORPH – First volunteer dosed in intranasal COVID-19 vaccine clinical trial January 11, 2021 – Posted in: Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces that the first volunteer has been dosed with the Codagenix Inc. (“Codagenix”) needle free, intranasal COVID-19 vaccine, COVI-VAC. Conducted by hVIVO, part of Open Orphan plc, the Phase I clinical trial of COVI-VAC is being carried out at their facility in the UK. COVI-VAC is a single-dose, intranasal, live…

Continue reading

Open Orphan #ORPH – MHRA approval for nasal COVID-19 vaccine clinical trial – Posted in: Uncategorized

First in human trials for vaccine candidate with the potential to confer long-term immunity Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials, announces the first in human (Phase I) study of Codagenix intranasal SARS-CoV-2 (COVID-19) vaccine candidate has received approval from the UK’s independent Medicines and Healthcare Products Regulatory Agency (MHRA). Further to the…

Continue reading

Daily Telegraph – When will a Covid-19 vaccine be ready in the UK? Latest updates from around the world September 30, 2020 – Posted in: Open Orphan (ORPH)

ByAnnelies Gartner ; Lizzie Roberts and Christopher Hope, Volunteers could soon be deliberately infected with coronavirus in trials to speed up a vaccine and discover if people are protected if they have already had the disease. In a groundbreaking trial, scheduled to begin in January at the Royal Free Hospital in London, patients will be inoculated with a vaccine developed by Imperial College, and then exposed to coronavirus. “Challenge trials” are controversial, but can give a quick…

Continue reading

Open Orphan #ORPH Awarded Contract From Codagenix Inc For COVID-19 Vaccine Trial July 27, 2020 – Posted in: Open Orphan (ORPH), Uncategorized

Tuesday 28th July, 2020 Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce a new contract with Codagenix Inc. (“Codagenix”) to conduct a first in human (Phase I) trial evaluating safety and immunogenicity of a single-dose, intranasal SARS-CoV-2 (COVID-19) vaccine candidate in 48 healthy young adult volunteers.   Highlights: First in human…

Continue reading